Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Belluscura confident in outlook after getting China approval
(Sharecast News) - Belluscura has gained approval to distribute its X-PLOR portable oxygen concentrator (POC) in China, it announced on Wednesday, under a licensing agreement with InnoMax Medical Device Technologies. The AIM-traded firm said discussions with Chinese distributors were underway, adding that the Asian POC market was expected to reach nearly $1bn in six years.
Looking at its current trading, Belluscura said that while 2023 results were slightly below expectations at the EBITDA level, prospects for 2024 remained unchanged.
Belluscura raised funds in October and anticipated additional resources from TMT Acquisition.
The company shifted its focus to the direct-to-consumer business in the second half of 2023, yielding higher-margin sales.
It said DISCOV-R was still garnering interest, with deposits received at a $3,000 list price.
The product was set for launch in early February, with total production in China expected by the third quarter of the year.
Belluscura said it expected a 50% increase in gross margin with a new aluminium sieve design, while CE and UKCA markings for X-PLOR were anticipated in the second quarter of 2024.
"We are delighted to have received approval in China which has taken over approximately 10 months," said chief executive officer Bob Rauker.
"This enables us to launch sales into China with immediate effect.
"With our arrangement with InnoMax in place, we are confident that we can now deliver on the significant potential for our products in this large and growing market."
Rauker said the approvals in China, Singapore, and Hong Kong were the first steps in leveraging the InnoMax agreement to expand in the ASEAN region and distribute portable oxygen concentrators in new markets.
"Building any start-up business is never easy, particularly within the MedTech world and the current economic environment.
"After two years of testing, developing and refining our products, the board is very confident that Belluscura is now well placed to take advantage of the significant opportunities it has in 2024 and beyond."
At 1338 GMT, shares in Belluscura were up 2.32% at 22p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
